Research Shows Prognostic Cardiovascular Tests Can Save $180 Million in Health Care Costs over Five Years

June 19, 2014

Analysis Group health care researchers partnered with Cleveland HeartLab (CHL) to develop an economic model to quantify the potential economic and clinical benefits of using multiple inflammatory biomarker tests to more accurately stratify near-term cardiovascular risk. The results of the study -- conducted by an Analysis Group team led by Principal Howard Birnbaum and Manager Mihran Yenikomshian -- demonstrate that adding cardiovascular inflammatory testing to standard cholesterol testing leads to substantial cost savings for U.S. health plans. The research also shows that averting mortality and morbidity from myocardial infarction and ischemic stroke -- through the use of routine testing of multi-tiered cardiovascular risk markers of vascular inflammation -- can save the U.S. health care system at least $180 million (before biomarker testing costs) over five years.

The results of the study were recently presented in a poster, "The Economic Impact of Implementing a Multiple Inflammatory Biomarker-Based Approach to Identify, Treat, and Reduce Cardiovascular Risk," on June 2, 2014, at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting in Montreal, Canada.

Read the CHL press release

Read more about our presence at the 2014 ISPOR Conference